iBio data shows IBIO-610 preserves muscle with semaglutide
A non-human primate study found that iBio's candidate IBIO-610 preserved muscle when combined with semaglutide. The company expects to start first-in-human trials in early 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed